Daneng Li, M.D.
- Liver Tumors
- Gallbladder Cancer
- Gastrointestinal Cancers
- Gastrointestinal Carcinoid Tumors
- Pancreatic Cancer
- Geriatric Oncology
- Bile Duct Cancer
- Liver Tumors
- Neuroendocrine Tumors
- Cancer and Aging
- Associate Professor, Department of Medical Oncology & Therapeutics Research
- Co-Director, Neuroendocrine Tumor Program
Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope.
Dr. Li earned his undergraduate degree from The Ohio State University in Columbus, Ohio, graduating summa cum laude. He then went on to receive his medical doctorate from Weill Cornell Medical College in New York, before pursuing an internship and residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. He then completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine and medical oncology, Dr. Li serves on several national committees focused on his specialty tumor types. He has authored several publications in the peer reviewed literature, and has presented his work nationally.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
- 2015, Diplomate, American Board of Medical Oncology
2009, M.D., Weill Cornell Medical College, New York, NY
2005, B.S., molecular genetics, summa cum laude, The Ohio State University, Columbus, OH
2012-2015, Fellow in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
2009-2012, Internship and Residency in Internal Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
- 2022 – Present, Associate Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center
- 2021 - Present, Assistant Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center
- 2015 - 2021, Assistant Clinical Professor, Department of Medical Oncology & Experimental Therapeutics, City of Hope National Medical Center
Awards & Memberships
AWARDS
- 2023 Blue Faery Award for Excellence in Liver Cancer Research
MEMBERSHIPS
- American Society of Clinical Oncology
- Cancer and Aging Research Group
- Phi Beta Kappa
- International Society of Geriatric Oncology
- Alliance Cancer in the Elderly Committee
- SWOG Gastrointestinal Cancer Committee
- NANETS Research Committee
Publications
- Li D, Crook C, Ballena R, Fakih M. Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution? JCO Oncol Pract. 2021 Feb 17:OP2001018. doi: 10.1200/OP.20.01018. Epub ahead of print. PMID: 33596100.
- Kessler J, Singh G, Ituarte PHG, Allen R, Chang S, Li D. A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. J Vasc Interv Radiol. 2021 Mar;32(3):393-402. doi: 10.1016/j.jvir.2020.10.019. Epub 2021 Jan 7. PMID: 33358144.
- Li D, Rock A, Kessler J, Ballena R, Hyder S, Mo C, Chang S, Singh G. Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician's Guide to a Complex Illness. JCO Oncol Pract. 2020 Nov;16(11):720-728. doi: 10.1200/JCOOP.20.00010. Epub 2020 Oct 21. PMID: 33085933.
- Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol. 2021 Jan;123(1):164-171. doi: 10.1002/jso.26230. Epub 2020 Sep 24. PMID: 32974932.
- Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci. 2020 Jul 23;21(15):5232. doi: 10.3390/ijms21155232. PMID: 32718047; PMCID: PMC7432744.
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. PMID: 32402160.
- Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930. PMID: 32352498; PMCID: PMC7193528.
- Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019 Jun 18;11(6):841. doi: 10.3390/cancers11060841. PMID: 31216701; PMCID: PMC6627588.
- Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018 Jun;19(6):e305-e316. doi: 10.1016/S1470-2045(18)30348-6. Epub 2018 Jun 1. PMID: 29893262.
- Li D, Soto-Perez-de-Celis E, Hurria A. Geriatric Assessment and Tools for Predicting Treatment Toxicity in Older Adults With Cancer. Cancer J. 2017 Jul/Aug;23(4):206-210. doi: 10.1097/PPO.0000000000000269. PMID: 28731942.